Euroapi (EAPI) Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EAPI from our risk checks.
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.08 |
| 52 Week High | €4.46 |
| 52 Week Low | €2.26 |
| Beta | 0.70 |
| 1 Month Change | -0.96% |
| 3 Month Change | -3.75% |
| 1 Year Change | -9.78% |
| 3 Year Change | -82.47% |
| 5 Year Change | n/a |
| Change since IPO | -77.21% |
Recent News & Updates
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Oct 03
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Aug 02Recent updates
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Oct 03Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Aug 02
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
Mar 06Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Oct 04There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Jul 29Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 24Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
Apr 10Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
Mar 03Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Mar 02A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Dec 21Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
Aug 04Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Aug 02Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
Jun 16An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Jan 25Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 38% Above Its Share Price
Oct 15Statutory Profit Doesn't Reflect How Good Euroapi's (EPA:EAPI) Earnings Are
Sep 09Shareholder Returns
| EAPI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -8.4% | -1.6% | -2.3% |
| 1Y | -9.8% | -2.1% | 9.7% |
Return vs Industry: EAPI underperformed the French Pharmaceuticals industry which returned -2.1% over the past year.
Return vs Market: EAPI underperformed the French Market which returned 9.7% over the past year.
Price Volatility
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 10.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: EAPI has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: EAPI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,187 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization.
Euroapi S.A. Fundamentals Summary
| EAPI fundamental statistics | |
|---|---|
| Market cap | €300.87m |
| Earnings (TTM) | -€124.30m |
| Revenue (TTM) | €882.80m |
Is EAPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAPI income statement (TTM) | |
|---|---|
| Revenue | €882.80m |
| Cost of Revenue | €761.80m |
| Gross Profit | €121.00m |
| Other Expenses | €245.30m |
| Earnings | -€124.30m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 03, 2026
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 13.71% |
| Net Profit Margin | -14.08% |
| Debt/Equity Ratio | 5.3% |
How did EAPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 20:38 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Euroapi S.A. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Andrew Wood | BofA Global Research |
| Falko Friedrichs | Deutsche Bank |
| Fynn Scherzler | Deutsche Bank |